Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus OGEN 1 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus OGEN 1 25.
ETHINYL ESTRADIOL AND NORELGESTROMIN vs OGEN 1.25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release via negative feedback on pituitary; progestin (norelgestromin) thickens cervical mucus and inhibits ovulation.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
One transdermal patch (releasing 0.035 mg ethinyl estradiol and 0.150 mg norelgestromin per 24 hours) applied once weekly for 3 weeks, followed by 1 week patch-free.
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
None Documented
None Documented
Ethinyl estradiol has a terminal elimination half-life of approximately 13-27 hours (mean ~17 hours). Norelgestromin has a terminal half-life of about 28 hours. These half-lives support once-weekly dosing of the transdermal system, achieving steady-state by the second application.
Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days
Ethinyl estradiol and norelgestromin are excreted primarily via urine and feces. Ethinyl estradiol undergoes extensive metabolism; about 40% is excreted in urine and 60% in feces as glucuronide and sulfate conjugates. Norelgestromin is metabolized to norgestrel and other metabolites; approximately 45% is excreted in urine and 35% in feces.
Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5%
Category D/X
Category C
Estrogen
Estrogen